BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Biotech Support Group Release: Research Article Cites AlbuSorb™ To Improve Urine Exosome Proteomic Study


2/17/2014 9:05:32 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MONMOUTH JUNCTION, NJ, Feb. 17, 2014 -- Biotech Support Group reports on a recent research article which describes the simplicity and efficiency of their proteomic sample preparation technology for albumin depletion. Urine exosome isolation via ultracentrifugation, followed by albumin depletion provides researchers with knowledge of renal regulation and could lead to the identification of biomarkers for diabetic nephropathy and diabetic mellitus. By removing albumin using AlbuSorb™, the authors identified more urinary proteins such as flotillin-2, lamp-1, PODXL, tsg-101 from exosome fractions of urine samples. The citation is:

Zubiri, Irene, Maria Posada-Ayala, Aroa Sanz-Maroto, Enrique Calvo, Marta Martin-Lorenzo, Laura Gonzalez-Calero, Fernando de la Cuesta et al. "Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis." Journal of Proteomics, 96 (2014): 92-102.

In brief, the article states that Diabetes mellitus leads to diabetic nephropathy (DN), ultimately causing end-stage renal disease (ESRD). So discovery of candidate biomarkers which identify the pathophysiological mechanism of DN remain important. Identification of such biomarker proteins from diabetic nephropathy (DN) and healthy human urine samples is challenged by the high abundance proteins present in urine, especially albumin and Tamm-Horsfall protein. Secreted microvesicles known as exosomes are linked to antigen expression, RNA and protein transport. Exosomes extracted from urine samples could become a rich source of urinary biomarkers, and may supplement serum creatinine and albumin excretion, for disease staging and clinical intervention. In this article, exosome isolation via ultracentrifugation, dithiothreitol (DTT) treatment, and albumin depletion of precipitated exosome fractions is described. Authors Zubiri et al, cite AlbuSorb™ for albumin depletion and further describe proteomic workflows for biomarker discovery from isolated urine exosomes. Subsequent LC-MS/MS and selected reaction monitoring (SRM) of urine exosome protein content from diabetic and healthy controls were analyzed. The research cites AMBP, MLL3, VDAC1 as proteins in urinary exosomes of diabetic nephropathy patients.

“This article further validates our unique surface technology, not based on antibodies or engineered bio-ligands, as being a highly selective and efficient method for the depletion of albumin from any biological source. I am delighted to see that such efficiencies lead to the enhanced contribution of proteomics to understand and treat disease.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

Characteristics of AlbuSorb™

Removes >90% albumin from 30 mg albumin/ml sample
Affinity-type equivalence, virtually no cross-reactivity with other proteins
Bind and elute procedure - simply weigh powder, condition the sample, centrifuge and/or filter, and recover the albumin depleted serum
Economical new surface technology, not based on biologically derived ligands
Mild conditions maintain tertiary structure of proteins and simple transfer to secondary analysis
The albumin depleted filtrate retains all enzymatic and biological activity
Tissue and species agnostic
The flow through fraction is compatible with LC-MS, activity based protein profiling and all proteomic analyses.

For more information visit: AlbuSorb ™ Albumin depletion kit visit
http://www.biotechsupportgroup.com/node/64

About Biotech Support Group LLC

Biotech Support Group LLC is a leading developer of proteomic, metabolomic and genomic sample preparation and enrichment products. It’s principal products include: AlbuVoid™ & AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption and clarification, HemogloBind™ & HemoVoid™ for hemoglobin removal, NuGel™ for functional & chemical proteomics, and ProCipitate™ & ProPrep™ for nucleic acid isolation. For more information, go to http://www.biotechsupportgroup.com

Contact:
Matthew Kuruc
Biotech Support Group
1 Deer Park Drive, Suite M
Monmouth Junction NJ 08852
732-274-2866 Worldwide
800-935-0628 North America
www.biotechsupportgroup.com
mkuruc@biotechsupportgroup.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES